Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

(StatePoint) When John noticed blood in his urine, he consulted his doctor and was quickly referred to a urologist. (John is a composite character, based on the experiences of real-life patients.) ...

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up (StatePoint) Like many bladder cancer survivors, Karen S. often ...

Receiving a diagnosis of stage 1 urothelial carcinoma (bladder cancer) can feel overwhelming, but at this stage, the cancer is highly treatable. Stage 1 means the cancer has grown into the inner ...

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

When using a diagnostic tool, it is common see to more false-positives as the number of true-positives increases ( Table 1). The accuracy of fluorescence cystoscopy is also affected by previous ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...